Post Archive by Month

Over the past two months, people confronting a specific type of bladder cancer have received some optimistic news.
Multiple cancer patients have been treated with ANKTIVA® less than eight weeks after the U.S. FDA approved ImmunityBio Inc.’s approved immunotherapy for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. 

While no approved vaccines target Parkenson's disease (PD), several clinical pathways are being investigated with innovative technologies in 2024. 
Different monoclonal antibodies have been investigated as passive immunization, and novel active immunization modalities targeting PD are being studied.
Recently, the findings of a non-peer-reviewed study reveal a significant reduction in PD occurrence following anti-tetanus vaccination, with a time-dependent association between the elapsed time since vaccination and the rate and progression of PD.

Bharat Biotech International Limited (BBIL) recently stated X that the company unintentionally omitted the Indian Council of Medical Research (ICMR) as a co-owner of the inactivated COVAXIN® vaccine patent.
On June 22, 2024, the Hyderabad-based vaccine producer Tweeted that it was taking legal action to correct this issue.
According to media reporting, ICMR was to receive a 5% royalty on net sales and product branding rights, which include 'co-inventor' status.

Gavi, the Vaccine Alliance, has confirmed it is seeking $9 billion in new funding to immunize children against more diseases faster than ever.
Dr. Sania Nishtar, CEO of Gavi, presented the latest Investment Opportunity on June 20, 2024, outlining how the Alliance, if fully funded, could protect 500 million children in its next five-year strategic period, potentially saving over 8 million lives.
Previously, Gavi vaccinated one billion children between 2000 and 2020.

Ever since 1947, when the Zika virus was first detected, people have been getting infected with this disease. In 2024, both Zika outbreaks and the development of preventive vaccines have accelerated.
Autochthonous mosquito-borne transmission of Zika has been detected in 89 countries and territories globally. 

The U.S. Centers for Disease Control and Prevention (CDC) recently confirmed a meeting of the Advisory Committee on Immunization Practices (ACIP) will be conducted from June 26-28, 2024.
The agenda for this ACUP meeting includes discussions of new and existing vaccines, such as:

Merck announced today that the U.S. Food and Drug Administration (FDA) has approved CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine). 
CAPVAXIVE (V116) is specifically designed to help protect adults against the serotypes that cause most invasive pneumococcal disease (IPD) cases. CAPVAXIVE includes eight unique serotypes not covered by other currently approved pneumococcal vaccines.